treatments for diseases that are rare, complex, or novel. In the past, DR was
considered tedious, as target identification required manual selection through litera-
ture searches. Modern approaches have advanced to incorporating knowledge-based
and machine learning information into databases that can provide valuable output of
target molecules and networks and ultimately lead to the identification of a func-
tional FDA-approved drug target to reposition for the disease of interest. Some
challenges of DR include concerns regarding intellectual property and the integra-
tion of the multitudinal approaches for DR, in particular, to incorporate vast amounts
of data across various computational tools and databases with advanced expertise.
DR is being recognized to provide hopeful outcomes for neglected and orphan
diseases as well as significant potential for the future of personalized medicine.
Overall, genomic approaches confer a more efficient and effective establishment of
drug targets for DR.
Author Contributions Authors contributed equally to the writing and preparation
of the review manuscript. S.K.L. contributed to the supervision of this manuscript.
All authors have read and agreed to the published version of the manuscript.
Funding Internal funds from Monash Malaysia and School of Science Strategic
Grant 2020.
Conflicts of Interest The authors declare no conflict of interest.
References
About Cystic Fibrosis (2021) CF foundation [Internet]. Available from: https://www.cff.org/What-
is-CF/About-Cystic-Fibrosis/
Alirol E, Schrumpf D, Amici Heradi J et al (2013) Nifurtimox-eflornithine combination therapy for
second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience
in the Democratic Republic of the Congo. Clin Infect Dis 56:195–203
Alzheimer Disease(2021) Genetic and rare diseases information center (GARD) – an NCATS
program [Internet]. Available from: https://rarediseases.info.nih.gov/diseases/10254/
alzheimer-disease
Arnone D (2005) Review of the use of topiramate for treatment of psychiatric disorders. Ann
General Psychiatry 4:5
Aronson JK (2006) Rare diseases and orphan drugs. Br J Clin Pharmacol 61:243–245
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing
drugs. Nat Rev Drug Discov 3:673–683
Biovista (2021) Drug positioning and prioritization - home [Internet]. Available from: https://www.
biovista.com/
Boekhout AH, Beijnen JH, Schellens JHM (2011) Trastuzumab. Oncologist 16:800–810.
Available from: https://onlinelibrary.wiley.com/doi/abs/10.1634/theoncologist.2010-0035
Bush WS, Moore JH (2012) Chapter 11: genome-wide association studies. PLoS Comput Biol 8:
e1002822. Available from: www.genome.gov/gwastudies
Cavalla D (2013) Predictive methods in drug repurposing: gold mine or just a bigger haystack?
Drug Discov Today 18:523–532. https://doi.org/10.1016/j.drudis.2012.12.009
68
I. A. Farouk et al.